JAZZ News and Press, Jazz Pharmaceuticals plc From 04/20/22

Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022 PR Newswire DUBLIN , April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on ...

Most cannabis stocks have seen their shares slide so far this year, but Jazz Pharmaceuticals (NASDAQ: JAZZ) , WM Technology (NASDAQ: MAPS) , and Glass House Brands (OTC: GLAS.F) , have all seen double-digit rises in their shares. All three companies are different...

The recent Sunosi acquisition delivers pipeline synergy as well as making Axsome revenue positive. AXS07 is poised to gain FDA approval to better serve patients afflicted by migraines. AXS05's regulatory issues are now seemingly cleared with approval anticipated for either Q3 or Q...

Best Medical Marijuana Stocks In 2022 Are top marijuana stocks on your radar for 2022? In April the cannabis sector continued to experience significant market volatility in the second quarter of the year. Overall, the stock market has been heavily affected by the War in Ukraine and ...

The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data. Contrary to market belief, I view Mirve as a stellar drug for the treatment of advanced ovarian cancer. I forecast a high likelihood of upcoming Mirve approval. For further details...

Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types PR Newswire Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated ...

Meme stocks GameStop and AMC Entertainment are flying high again with their shares up over 30% in the past month while the S&P 500 has risen by a more modest 6%. But rather than getting caught up in what has been a volatile cycle involving these two stocks over the past year...

Jazz Pharmaceuticals (NASDAQ:JAZZ) has signed an exclusive licensing agreement with recently-IPO’ed Werewolf Therapeutics (NASDAQ:HOWL) to acquire the exclusive global rights for cancer candidate WTX-613 from Werewolf, the companies announced on Thursday. In addition to $15 million of ...

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule PR Newswire Werewolf to receive $15 million upfront paym...

Following three consecutive sessions of gains, Jazz Pharmaceuticals (NASDAQ:JAZZ -3.3%) is trading lower in the morning hours Wednesday after Morgan Stanley downgraded the neurology-focused pharma company citing the recent outperformance in its shares. Noting that Jazz (JAZZ) has climbed more...